# A Study of LY2584702 in Participants With Advanced Cancer

> **NCT01394003** · PHASE1 · TERMINATED · sponsor: **Eli Lilly and Company** · enrollment: 34 (actual)

## Conditions studied

- Advanced Cancer

## Interventions

- **DRUG:** LY2584702

## Key facts

- **NCT ID:** NCT01394003
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-11
- **Primary completion:** 2011-04
- **Final completion:** 2011-04
- **Target enrollment:** 34 (ACTUAL)
- **Why stopped:** The pharmacokinetic properties of the molecule do not allow for further dose escalation or development.
- **Last updated:** 2019-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01394003

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01394003, "A Study of LY2584702 in Participants With Advanced Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01394003. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*